CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Frailty and Bleeding in Older Adults Undergoing TAVR or SAVR: Insights From the FRAILTY-AVR Study 2019 ACC/AHA/ASE Advanced Training Statement on Echocardiography (Revision of the 2003 ACC/AHA Clinical Competence Statement on Echocardiography): A Report of the ACC Competency Management Committee Minimalist transcatheter aortic valve replacement: The new standard for surgeons and cardiologists using transfemoral access? Systemic microvascular dysfunction in microvascular and vasospastic angina Serial intravascular ultrasound assessment of very late stent thrombosis after sirolimus-eluting stent placement Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Subgroup Analysis From ULTIMATE Trial The prevalence and importance of frailty in heart failure with reduced ejection fraction - an analysis of PARADIGM-HF and ATMOSPHERE Extreme Levels of Air Pollution Associated With Changes in Biomarkers of Atherosclerotic Plaque Vulnerability and Thrombogenicity in Healthy Adults

Original Research

JOURNAL:ACC Article Link

房颤合并慢性肾病的抗凝策略

CBSMD

Pre-reading

房颤(Atrial fibrillation, AF)和慢性肾脏疾病( chronic kidney disease ,CKD)的多种致病因素常存在共通性,高血压、糖尿病和冠状动脉疾病。当不合并CKD时,对房颤患者开展抗凝治疗是毋庸置疑的,但此做法不适用于房颤合并晚期CKD的患者群(advanced CKD)。随着CKD患者肾功能的下降,缺血性卒中和出血的危险逐渐增加,使抗凝治疗趋向复杂。现存随机对照试验尚不能得出明确辅助临床决策的指南性意见,而观察性研究的结果相互矛盾。在最新JACC综述Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week,作者概述了相关病理生理学机制,总结CKD合并AF的抗凝策略及研究进展, 并就如何在这些患者中使用口服抗凝给出建议

该文核心要点可参阅CBSMD文献导读Anticoagulation in Concomitant CKD and AF”。